Interventional radiology technology developer Surefire Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Surefire Precision, a new infusion drug delivery device.
Surefire Precision has an expandable tip that increases drug delivery into tumors while protecting healthy tissue. A recent clinical study in the Journal of Vascular and Interventional Radiology found that the technology increased the uptake of particles by an average of 68% and up to 90%, compared with the use of conventional end-hole catheters for treating primary liver cancer, according to the company.
Surefire Medical believes that the technology will give interventional radiologists and interventional oncologists more selectivity in accessing smaller peripheral blood vessels in patients, particularly for liver cancer patients.
